Sanofi-Aventis Inaugurates First Asian Development Centre for Pharmaceuticals in Goa, India
- Largest single investment in India to date -
PARIS, Dec. 3, 2007-Sanofi-aventis celebrated today the opening of its first Asian pharmaceutical development centre in Goa, India. The investment in the Goa development centre (GDC) represents the group’s single largest investment in India to date and is testament to sanofi-aventis’ strategy to expand its presence and accelerate growth both in India and in Asia. As sanofi-aventis’ first Asian hub for analytical and pharmaceutical formulation development, the 2, 600 square metres GDC will have the capacity to develop up to 12 pharmaceutical compounds per year. Located close to sanofi-aventis’ state of the art manufacturing facility in Goa, it will play a pivotal role in allowing the group to introduce new, quality medicines rapidly both in Asia Pacific and the global marketplace.
“I am very pleased to inaugurate the Goa development centre which will serve to expand sanofi-aventis’ capacity to develop and produce medicines adapted to local market needs in an efficient and cost-effective manner. The GDC will be a cornerstone of our success in Asia and should enable us to leverage our formulation development efforts worldwide”, said Olivier Charmeil, Senior Vice President Asia Pacific.
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT:
SAN) and in New York (NYSE: SNY).
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans” and similar expressions. Although sanofi-aventis’ management believes that the expectations reflected in such forwardlooking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward- Looking Statements” in sanofi-aventis’ annual report on Form 20-F for the year ended December 31, 2006. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.
Posted: December 2007